trial

Psychotherapy for Psychosis, Adverse Events, and Substance Misuse

NCTId NCT04546178
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 19 (actual)
Sponsored by Nova Scotia Health Authority
Primary completion 2023-09-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
19 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Single
Start
2021-11-15
Primary completion
2023-09-15
Eligibility
ALL · 19 Years · 35 Years

Interventions & indications

Drugs
Prolonged exposure (PE)+ therapy

Sponsors

Nova Scotia Health AuthorityLead Sponsor
Queen Elizabeth II Health Sciences Centre FoundationCollaborator
Research Nova ScotiaCollaborator
Killam LaureatesCollaborator

Investigators

1
Victoria Patterson, PhD studentPrincipal Investigator

Sites

1 total
Halifax, Canada

Facts & assertions

4 sourced
Enrollment
19
Phase
NA
Primary Completion Date
2023-09-15
Status
COMPLETED
relationships
The graph out of here
drug
Prolonged exposure (PE)+ therapy
drug
lead_sponsor
Nova Scotia Health Authority
company
collaborator
Queen Elizabeth II Health Sciences Centre Foundation
company
Research Nova Scotia
company
indication
Psychotic Disorders
indication
Substance Use
indication
Stress Disorders, Traumatic
indication
investigator
Victoria Patterson, PhD student
person